Auris Medical Holding AG (NASDAQ:EARS) has received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price target of $12.00 for the company and are anticipating that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Auris Medical Holding AG an industry rank of 61 out of 265 based on the ratings given to related companies.
Auris Medical Holding AG (NASDAQ:EARS) opened at 5.08 on Monday. The stock’s market capitalization is $174.21 million. The stock has a 50 day moving average price of $3.56 and a 200-day moving average price of $4.25. Auris Medical Holding AG has a 1-year low of $3.02 and a 1-year high of $7.15.
Auris Medical Holding AG (NASDAQ:EARS) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.13. Equities research analysts expect that Auris Medical Holding AG will post ($1.14) EPS for the current year.
EARS has been the topic of a number of recent analyst reports. Leerink Swann reaffirmed an “outperform” rating on shares of Auris Medical Holding AG in a research report on Tuesday, October 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Auris Medical Holding AG in a research report on Thursday, October 1st. Finally, Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Tuesday, November 17th.
Auris Medical Holding AG is a holding company. The Company is a development-stage biopharmaceutical company. The Company’s advanced product candidate is AM-101 for acute inner ear tinnitus. It is also developing AM-111 for acute inner ear hearing loss. Its product candidates are injected under local anesthesia into the middle ear by a technique called intratympanic, or i.t., injection. The Company is also engaged in preclinical studies of AM-102 and AM-123. AM-101 is formulated in a biocompatible gel. AM-111 contains a synthetic D-form peptide (NASDAQ:EARS) that protects sensorineural structures in the inner ear from stress-induced damage. AM-111 is being developed for the treatment of autoimmune sensorineural hearing loss (ASNHL).
For more information about research offerings from Zacks Investment Research, visit Zacks.com